Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy

Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy

The endothelin axis, recognized for its vasoconstrictive action, plays a central role in the pathology of pulmonary arterial hypertension (PAH). Treatment with approved endothelin receptor antagonists (ERAs), such as bosentan, ambrisentan, or macitentan, slow down PAH progression and relieves sympto...

Full description

Bibliographic Details
Main Authors: Frederik C. Enevoldsen, Jayashree Sahana, Markus Wehland, Daniela Grimm, Manfred Infanger, Marcus Krüger
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Journal of Clinical Medicine
Subjects:
pulmonary arterial hypertension
cancer
renal disease
fibrotic disorders
systemic scleroderma
cerebral vasospasm
pain management
ambrisentan
atrasentan
bosentan
clazosentan
macitentan
zibotentan
Online Access:https://www.mdpi.com/2077-0383/9/3/824

Internet

https://www.mdpi.com/2077-0383/9/3/824

Similar Items